Hepatitis A Vaccine Dosing Regimens Among Pediatric Patients on Immunosuppressive Therapy

Exclusion Criteria

• •Systemic hypersensitivity to any Hepatitis A vaccine component such as neomycin, 2-phenoxyethanol, formaldehyde, aluminum hydroxide, Medium 199 Hanks, or Polysorbate 80.
• •Thrombocytopenia or any bleeding disorder that contraindicates IM injection or blood collection.
• •Receipt of blood or any blood-derived products (including IVIG) within the past 3 months.
• •Previous laboratory-confirmed infection with Hepatitis A
• •Previous vaccination with any Hepatitis A vaccine
• •Current febrile illness or oral temperature of ≥ 38.5 °C (or equivalent by other route) or other moderate to severe illness within 24 hours before study vaccine administration
• •Receipt of any Hepatitis B vaccine within 28 days of planned study vaccine doses. When Twinrix® has been studied, the response to Hepatitis B is amplified by the presence of Hepatitis A. It is unknown whether the reverse is also true.
• •Routine childhood vaccines (except MMR and Varicella) must be separated from a study vaccination by at least 7 days.